Oncoptpeptides - Bring hope through science

Bringing hope through science

David Augustsson, Director of Corporate Affairs

Oncopeptides appoints David Augustsson as Director of Corporate Affairs

Oncopeptides AB today announced that David Augustsson has been appointed Director of Corporate Affairs. As part of the company leadership team, David will be responsible for corporate communications, including strengthening the relationship with its broad investor base, and also drive the effort to reshape the corporate strategy of the company and enable the execution of it.

Read more

Annual General Meeting on May 25

On Thursday, May 25, Oncopeptides hosted its 2023 Annual General Meeting. Be sure to watch the presentation held by Oncopeptides CEO Monica Shaw, or follow this link to find more information, including the bulletin from the meeting and the filmed Q&A session.

Read more


Interim report Q1 2023

”Pepaxti providing clinical benefit to patients with Multiple Myeloma”

Monica Shaw, CEO


See the Webcast

For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications


Interim Report Q2,
August 10, 2023

Profile image

Press release -

The Swedish Economic Crime Authority terminates the investigation of Oncopeptide's Chief Scientific Officer Jakob Lindberg

Read press release
Events Oncopeptides

Upcoming events

View calendar

Presentation of the Q1 Interim Report 2023

Oncopeptides published the report for the first quarter 2023, at 08.00 (CET) on Thursday May 4, 2023, and hosted a webcast on the same day at 09:00 (CET).

Investors, financial analysts, and media were invited to participate in the webcast and following QnA. The presentation was hosted by Monica Shaw, CEO, together with Holger Lembrér, CFO, and was held in English. The webcast was recorded. 

Link to the webcast and more information


Annual Report 2022

Letter from the CEO - Providing clinical benefit to patients


For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

Profile image
Monica Shaw CEO Oncopeptides

Monica Shaw appointed CEO

On January 4, 2023, Oncopeptides announced that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately.

Read the press release

Oncopeptides vision

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Oncopeptides via e-mail